Conference call to take place on Wednesday November 15 at 8:30 a.m. U.S Eastern Time
HENDERSON, Nev., Nov. 8, 2023
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)
("Volition") today announced it will host a conference call on
Wednesday, November 15 at
8.30 a.m. U.S. Eastern Time to
discuss its financial and operating results for the third quarter
2023, in addition to providing a business update. Details of this
event can also be found below.
Event: VolitionRx Limited Third Quarter 2023
Earnings and Business Update Conference
Call
Date: Wednesday, November 15, 2023
Time: 8:30
a.m. U.S. Eastern Time
U.S. & Canada Dial-in:1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13742634
Cameron Reynolds, President and
Group Chief Executive Officer of Volition, will host the call along
with Terig Hughes, Group Chief Financial Officer, Dr. Tom Butera, Chief Executive Officer of Volition
Veterinary Diagnostics Development LLC, Dr. Andrew Retter, Medical Consultant to Volition
and Scott Powell, Executive Vice
President, Investor Relations. The call will provide an update on
important events which have taken place in the third quarter of
2023 and upcoming milestones.
A live audio webcast of the conference call will also be
available on the investor relations page of Volition's corporate
website at https://ir.volition.com. In addition, a telephone replay
of the call will be available until November
29, 2023. The replay dial-in numbers are 1-844-512-2921
(toll-free) in the U.S. and Canada
and 1-412-317-6671 (toll) internationally. Please use replay pin
number 13742634.
About Volition
Volition is a multi-national epigenetics company focused on
advancing the science of epigenetics. Volition is dedicated to
saving lives and improving outcomes for people and animals with
life-altering diseases through earlier detection, disease and
treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential to not only prolong the
life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is
included in this document as an inactive textual reference
only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
View original
content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-third-quarter-2023-earnings-conference-call-and-business-update-301981625.html
SOURCE VolitionRx Limited